Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2025 | Key challenges in overcoming resistance to FLT3 inhibitors in AML

Alexander Perl • 3 Sep 2025
SOHO 2025
Acute Myeloid Leukemia Leukemia Gilteritinib Quizartinib

In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on the challenges of overcoming resistance to FLT3 inhibitors in acute myeloid leukemia (AML), noting that the mechanisms of resistance in frontline therapy may differ from those in relapsed/refractory settings. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Alexander Perl

Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
2:39
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
Alexander Perl • 5 Dec 2025
Optimizing therapy and extending survival in AML: balancing efficacy and toxicity
1:46
Optimizing therapy and extending survival in AML: balancing efficacy and toxicity
Alexander Perl • 5 Sep 2025
Approaches to managing FLT3-mutant AML
12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals